Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia

PURPOSE: To evaluate the clinical activity of sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive AML and monitor the emergence of secondary FLT3 tyrosine kinase domain (TKD) mutations during treatment. EXPERIMENTAL DESIGN: Six children with relapsed/refractory AML were treated with...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Baker, Sharyn D., Zimmerman, Eric I., Wang, Yong-Dong, Orwick, Shelley, Zatechka, Douglas S., Buaboonnam, Jassada, Neale, Geoffrey A., Olsen, Scott R., Enemark, Eric J., Shurtleff, Sheila, Rubnitz, Jeffrey E., Mullighan, Charles G., Inaba, Hiroto
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3878304/
https://ncbi.nlm.nih.gov/pubmed/23969938
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-1323
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items